LGND
Ligand Pharmaceuticals Incorporated$254.35-0.22 (-0.09%)Prev Close$254.57·MCap$5.10B·P/E34.51·Vol202.0K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
25
$16.47M
◆
Net Activity
Net Seller
$16.47M
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Ligand Pharmaceuticals Incorporated (LGND) has been exclusively selling, with 0 insider purchases totaling $0.00 and 25 insider sales totaling $16.47M. The most recent insider transaction was by LAMATTINA JOHN L (director), who sold $1.15M worth of shares on Jun 12, 2026. Ligand Pharmaceuticals Incorporated operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $5.10B.
LGND Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | LAMATTINA JOHN L | director | Sell | 4,591 | $250.88 | $1.15M | 31,303 |
| Jun 12, 2026 | Aryeh Jason | director | Sell | 5,000 | $250.00 | $1.25M | 107,080 |
| Jun 2, 2026 | Reardon Andrew | officer: CLO & Secretary | Sell | 5,000 | $227.06 | $1.14M | 45,891 |
| May 14, 2026 | KOZARICH JOHN W | director | Sell | 2,501 | $225.14 | $563.1K | 42,173 |
| May 4, 2026 | Reardon Andrew | officer: CLO & Secretary | Sell | 5,000 | $231.31 | $1.16M | 45,782 |
| Apr 2, 2026 | KOZARICH JOHN W | director | Sell | 467 | $202.23 | $94.4K | 42,574 |
| Apr 2, 2026 | Reardon Andrew | officer: CLO & Secretary | Sell | 5,000 | $201.24 | $1.01M | 45,922 |
| Mar 31, 2026 | LAMATTINA JOHN L | director | Sell | 2,161 | $200.76 | $433.8K | 30,724 |
| Mar 25, 2026 | Sabba Stephen L | director | Sell | 1,000 | $207.87 | $207.9K | 32,793 |
| Mar 13, 2026 | Espinoza Octavio | officer: Chief Financial Officer | Sell | 3,057 | $225.00 | $687.8K | 21,010 |
| Mar 6, 2026 | Espinoza Octavio | officer: Chief Financial Officer | Sell | 13,423 | $205.83 | $2.76M | 34,386-28% |
| Mar 6, 2026 | Reardon Andrew | officer: CLO & Secretary | Sell | 4,900 | $206.50 | $1.01M | 41,769 |
| Feb 4, 2026 | KOZARICH JOHN W | director | Sell | 444 | $195.93 | $87.0K | 43,615 |
| Jan 6, 2026 | KOZARICH JOHN W | director | Sell | 467 | $189.58 | $88.5K | 44,100 |
| Dec 16, 2025 | Espinoza Octavio | Chief Financial Officer | Sell | 1,804 | $188.31 | $339.7K | 26,186 |
| Dec 3, 2025 | KOZARICH JOHN W | Director | Sell | 467 | $195.84 | $91.5K | 44,496 |
| Nov 12, 2025 | Gray Nancy Ryan | Director | Sell | 6,571 | $205.45 | $1.35M | 8,094-45% |
| Nov 12, 2025 | LAMATTINA JOHN L | Director | Sell | 4,179 | $205.45 | $858.6K | 30,724 |
| Nov 5, 2025 | KOZARICH JOHN W | Director | Sell | 467 | $191.05 | $89.2K | 44,971 |
| Oct 3, 2025 | KOZARICH JOHN W | Director | Sell | 467 | $179.44 | $83.8K | 45,498 |
| Sep 24, 2025 | Aryeh Jason | Director | Sell | 10,000 | $170.81 | $1.71M | 74,871 |
| Sep 4, 2025 | KOZARICH JOHN W | Director | Sell | 467 | $162.26 | $75.8K | 45,722 |
| Aug 5, 2025 | KOZARICH JOHN W | Director | Sell | 467 | $131.88 | $61.6K | 45,989 |
| Jul 11, 2025 | KOZARICH JOHN W | Director | Sell | 934 | $125.00 | $116.8K | 46,456 |
| Jun 24, 2025 | Reardon Andrew | CLO & Secretary | Sell | 500 | $114.08 | $57.0K | 31,903 |
| Jun 12, 2025 | Reardon Andrew | CLO & Secretary | Sell | 500 | $114.54 | $57.3K | 32,403 |
| Jun 2, 2025 | Reardon Andrew | CLO & Secretary | Sell | 1,000 | $104.00 | $104.0K | 32,903 |
| May 13, 2025 | Davis Todd C | Chief Executive Officer | Buy | 9,510 | $105.20 | $1.00M | 161,234 |
| May 13, 2025 | Espinoza Octavio | Chief Financial Officer | Buy | 1,500 | $104.06 | $156.1K | 27,932 |
| Mar 6, 2025 | Espinoza Octavio | Chief Financial Officer | Sell | 5,000 | $115.03 | $575.1K | 18,879 |
| Dec 26, 2024 | Espinoza Octavio | Chief Financial Officer | Sell | 2,104 | $116.37 | $244.8K | 20,647 |
| Dec 2, 2024 | LAMATTINA JOHN L | Director | Sell | 2,406 | $123.65 | $297.5K | 29,515 |
| Sep 25, 2024 | Reardon Andrew | CLO & Secretary | Sell | 2,000 | $99.60 | $199.2K | 22,534 |
| Sep 24, 2024 | Espinoza Octavio | Chief Financial Officer | Sell | 1,275 | $103.94 | $132.5K | 25,685 |
| Sep 24, 2024 | Korenberg Matthew E | President & COO | Sell | 16,047 | $102.35 | $1.64M | 58,068 |
| Aug 30, 2024 | Reardon Andrew | CLO & Secretary | Sell | 1,500 | $106.39 | $159.6K | 22,534 |
| Aug 26, 2024 | Korenberg Matthew E | President & COO | Sell | 18,858 | $105.34 | $1.99M | 67,211 |
| Aug 13, 2024 | Korenberg Matthew E | President & COO | Sell | 18,245 | $98.50 | $1.80M | 68,368 |
| Aug 9, 2024 | Davis Todd C | Chief Executive Officer | Buy | 2,500 | $97.39 | $243.5K | 123,010 |
| May 17, 2024 | Espinoza Octavio | Chief Financial Officer | Sell | 13,293 | $86.26 | $1.15M | 23,882-36% |
| May 17, 2024 | Gray Nancy Ryan | Director | Sell | 934 | $83.20 | $77.7K | 5,633 |
| May 15, 2024 | Korenberg Matthew E | President & Chief Operating | Sell | 17,598 | $84.99 | $1.50M | 100,421 |
| May 13, 2024 | Reardon Andrew | Chief Legal Officer & | Sell | 10,000 | $83.04 | $830.4K | 22,205-31% |
| Mar 7, 2024 | Sabba Stephen L | Director | Sell | 1,893 | $74.30 | $140.7K | 28,926 |
| Feb 29, 2024 | Espinoza Octavio | Chief Financial Officer | Sell | 140 | $88.46 | $12.4K | 29,755 |
| Sep 25, 2023 | Davis Todd C | CHIEF EXECUTIVE OFFICER | Buy | 4,000 | $59.38 | $237.5K | 73,090 |
| May 18, 2023 | KOZARICH JOHN W | Director | Sell | 4,444 | $77.20 | $343.1K | 38,488 |
| May 12, 2023 | Sabba Stephen L | Director | Sell | 6,408 | $77.13 | $494.2K | 25,784 |
| May 10, 2023 | KOZARICH JOHN W | Director | Sell | 6,408 | $76.56 | $490.6K | 42,802 |
| Mar 28, 2023 | Reardon Andrew | See Remarks | Sell | 300 | $69.92 | $21.0K | 16,308 |
Showing 1–50 of 60
1 / 2
LGND Insider Buying Activity
The following table shows recent insider purchases of Ligand Pharmaceuticals Incorporated (LGND) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 13, 2025 | Davis Todd C | Chief Executive Officer | Buy | 9,510 | $105.20 | $1.00M | 161,234 |
| May 13, 2025 | Espinoza Octavio | Chief Financial Officer | Buy | 1,500 | $104.06 | $156.1K | 27,932 |
| Aug 9, 2024 | Davis Todd C | Chief Executive Officer | Buy | 2,500 | $97.39 | $243.5K | 123,010 |
| Sep 25, 2023 | Davis Todd C | CHIEF EXECUTIVE OFFICER | Buy | 4,000 | $59.38 | $237.5K | 73,090 |
LGND Insider Selling Activity
The following table shows recent insider sales of Ligand Pharmaceuticals Incorporated (LGND) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | LAMATTINA JOHN L | director | Sell | 4,591 | $250.88 | $1.15M | 31,303 |
| Jun 12, 2026 | Aryeh Jason | director | Sell | 5,000 | $250.00 | $1.25M | 107,080 |
| Jun 2, 2026 | Reardon Andrew | officer: CLO & Secretary | Sell | 5,000 | $227.06 | $1.14M | 45,891 |
| May 14, 2026 | KOZARICH JOHN W | director | Sell | 2,501 | $225.14 | $563.1K | 42,173 |
| May 4, 2026 | Reardon Andrew | officer: CLO & Secretary | Sell | 5,000 | $231.31 | $1.16M | 45,782 |
| Apr 2, 2026 | KOZARICH JOHN W | director | Sell | 467 | $202.23 | $94.4K | 42,574 |
| Apr 2, 2026 | Reardon Andrew | officer: CLO & Secretary | Sell | 5,000 | $201.24 | $1.01M | 45,922 |
| Mar 31, 2026 | LAMATTINA JOHN L | director | Sell | 2,161 | $200.76 | $433.8K | 30,724 |
| Mar 25, 2026 | Sabba Stephen L | director | Sell | 1,000 | $207.87 | $207.9K | 32,793 |
| Mar 13, 2026 | Espinoza Octavio | officer: Chief Financial Officer | Sell | 3,057 | $225.00 | $687.8K | 21,010 |
| Mar 6, 2026 | Espinoza Octavio | officer: Chief Financial Officer | Sell | 13,423 | $205.83 | $2.76M | 34,386-28% |
| Mar 6, 2026 | Reardon Andrew | officer: CLO & Secretary | Sell | 4,900 | $206.50 | $1.01M | 41,769 |
| Feb 4, 2026 | KOZARICH JOHN W | director | Sell | 444 | $195.93 | $87.0K | 43,615 |
| Jan 6, 2026 | KOZARICH JOHN W | director | Sell | 467 | $189.58 | $88.5K | 44,100 |
| Dec 16, 2025 | Espinoza Octavio | Chief Financial Officer | Sell | 1,804 | $188.31 | $339.7K | 26,186 |
| Dec 3, 2025 | KOZARICH JOHN W | Director | Sell | 467 | $195.84 | $91.5K | 44,496 |
| Nov 12, 2025 | Gray Nancy Ryan | Director | Sell | 6,571 | $205.45 | $1.35M | 8,094-45% |
| Nov 12, 2025 | LAMATTINA JOHN L | Director | Sell | 4,179 | $205.45 | $858.6K | 30,724 |
| Nov 5, 2025 | KOZARICH JOHN W | Director | Sell | 467 | $191.05 | $89.2K | 44,971 |
| Oct 3, 2025 | KOZARICH JOHN W | Director | Sell | 467 | $179.44 | $83.8K | 45,498 |
| Sep 24, 2025 | Aryeh Jason | Director | Sell | 10,000 | $170.81 | $1.71M | 74,871 |
| Sep 4, 2025 | KOZARICH JOHN W | Director | Sell | 467 | $162.26 | $75.8K | 45,722 |
| Aug 5, 2025 | KOZARICH JOHN W | Director | Sell | 467 | $131.88 | $61.6K | 45,989 |
| Jul 11, 2025 | KOZARICH JOHN W | Director | Sell | 934 | $125.00 | $116.8K | 46,456 |
| Jun 24, 2025 | Reardon Andrew | CLO & Secretary | Sell | 500 | $114.08 | $57.0K | 31,903 |
| Jun 12, 2025 | Reardon Andrew | CLO & Secretary | Sell | 500 | $114.54 | $57.3K | 32,403 |
| Jun 2, 2025 | Reardon Andrew | CLO & Secretary | Sell | 1,000 | $104.00 | $104.0K | 32,903 |
| Mar 6, 2025 | Espinoza Octavio | Chief Financial Officer | Sell | 5,000 | $115.03 | $575.1K | 18,879 |
| Dec 26, 2024 | Espinoza Octavio | Chief Financial Officer | Sell | 2,104 | $116.37 | $244.8K | 20,647 |
| Dec 2, 2024 | LAMATTINA JOHN L | Director | Sell | 2,406 | $123.65 | $297.5K | 29,515 |
| Sep 25, 2024 | Reardon Andrew | CLO & Secretary | Sell | 2,000 | $99.60 | $199.2K | 22,534 |
| Sep 24, 2024 | Espinoza Octavio | Chief Financial Officer | Sell | 1,275 | $103.94 | $132.5K | 25,685 |
| Sep 24, 2024 | Korenberg Matthew E | President & COO | Sell | 16,047 | $102.35 | $1.64M | 58,068 |
| Aug 30, 2024 | Reardon Andrew | CLO & Secretary | Sell | 1,500 | $106.39 | $159.6K | 22,534 |
| Aug 26, 2024 | Korenberg Matthew E | President & COO | Sell | 18,858 | $105.34 | $1.99M | 67,211 |
| Aug 13, 2024 | Korenberg Matthew E | President & COO | Sell | 18,245 | $98.50 | $1.80M | 68,368 |
| May 17, 2024 | Espinoza Octavio | Chief Financial Officer | Sell | 13,293 | $86.26 | $1.15M | 23,882-36% |
| May 17, 2024 | Gray Nancy Ryan | Director | Sell | 934 | $83.20 | $77.7K | 5,633 |
| May 15, 2024 | Korenberg Matthew E | President & Chief Operating | Sell | 17,598 | $84.99 | $1.50M | 100,421 |
| May 13, 2024 | Reardon Andrew | Chief Legal Officer & | Sell | 10,000 | $83.04 | $830.4K | 22,205-31% |
| Mar 7, 2024 | Sabba Stephen L | Director | Sell | 1,893 | $74.30 | $140.7K | 28,926 |
| Feb 29, 2024 | Espinoza Octavio | Chief Financial Officer | Sell | 140 | $88.46 | $12.4K | 29,755 |
| May 18, 2023 | KOZARICH JOHN W | Director | Sell | 4,444 | $77.20 | $343.1K | 38,488 |
| May 12, 2023 | Sabba Stephen L | Director | Sell | 6,408 | $77.13 | $494.2K | 25,784 |
| May 10, 2023 | KOZARICH JOHN W | Director | Sell | 6,408 | $76.56 | $490.6K | 42,802 |
| Mar 28, 2023 | Reardon Andrew | See Remarks | Sell | 300 | $69.92 | $21.0K | 16,308 |
LGND Insiders
Espinoza Octavio
officer: Chief Financial Officer
Bought $156.1KSold $6.03M
10 tradesLast: Mar 13, 2026
Similar Stocks to LGND
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B